

Bumrungrad Hospital Public Company Limited
and its subsidiaries
Review report and interim consolidated financial statements
For the three-month and six-month periods ended
30 June 2017

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Bumrungrad Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Bumrungrad Hospital Public Company Limited and its subsidiaries as at 30 June 2017, the related consolidated statements of income and comprehensive income for the three-month and six-month periods ended 30 June 2017, and the related consolidated statements of changes in shareholders' equity, and cash flows for the six-month period then ended, as well as the condensed notes to the consolidated financial statements. I have also reviewed the separate financial information of Bumrungrad Hospital Public Company Limited for the same periods. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*.

Termphong Opanaphan

Certified Public Accountant (Thailand) No. 4501

EY Office Limited

Bangkok: 9 August 2017

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		
	Note	30 June 2017	31 December 2016	30 June 2017	31 December 2016
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Assets					
Current assets					
Cash and cash equivalents		4,439,196	5,154,161	4,223,914	4,938,523
Short-term investments		3,377,300	1,523,300	3,309,000	1,509,000
Trade and other receivables	3	1,449,426	1,695,473	1,447,366	1,692,245
Inventories		306,045	310,014	270,415	279,917
Prepaid expenses		116,002	107,059	100,377	87,476
Other current assets		26,778	12,631	18,622	9,889
Total current assets		9,714,747	8,802,638	9,369,694	8,517,050
Non-current assets					
Investments in subsidiaries	4	-	-	1,638,773	1,638,773
Investments in associates	5	240,230	236,280	1,447	1,447
Other long-term investment		1,700	1,700	1,700	1,700
Property, plant and equipment	6	11,454,843	11,579,033	9,872,850	9,981,453
Intangible assets		328,775	315,047	323,054	309,409
Goodwill	7	115,427	121,709	-	-
Deferred tax assets		270,107	249,607	265,013	244,718
Other non-current assets		34,457	23,849	34,333	23,714
Total non-current assets		12,445,539	12,527,225	12,137,170	12,201,214
Total assets		22,160,286	21,329,863	21,506,864	20,718,264

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position (continued)

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		
	Note	30 June 2017	31 December 2016	30 June 2017	31 December 2016
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity					
Current liabilities					
Trade and other payables	8	864,772	875,614	846,464	869,510
Accrued physicians' fees		563,704	596,925	556,169	590,093
Accrued expenses		399,043	447,321	391,542	435,433
Income tax payable		437,847	364,574	419,192	352,574
Other current liabilities		73,780	73,662	52,374	51,291
Total current liabilities		2,339,146	2,358,096	2,265,741	2,298,901
Non-current liabilities					
Long-term loan from and interest payable to a related party	2	186,497	185,294	186,497	185,294
Long-term loan from and interest payable to an unrelated party		18,745	19,649	-	-
Long-term debentures	9	3,486,354	3,484,541	3,486,354	3,484,541
Deferred tax liability		2,035	1,820	-	-
Provision for long-term employee benefits	10	526,072	492,516	519,268	485,802
Total non-current liabilities		4,219,703	4,183,820	4,192,119	4,155,637
Total liabilities		6,558,849	6,541,916	6,457,860	6,454,538

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position (continued)

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		30 June 2017 (Unaudited but reviewed)	31 December 2016 (Audited)	30 June 2017 (Unaudited but reviewed)	31 December 2016 (Audited)
Shareholders' equity					
Share capital	11				
Registered					
921,339,320 ordinary shares of Baht 1 each (31 December 2016: 921,296,022 ordinary shares of Baht 1 each)		921,339	921,296	921,339	921,296
1,363,365 preference shares of Baht 1 each (31 December 2016: 1,406,663 preference shares of Baht 1 each)		1,364	1,407	1,364	1,407
		<u>922,703</u>	<u>922,703</u>	<u>922,703</u>	<u>922,703</u>
Issued and paid-up					
728,688,857 ordinary shares of Baht 1 each (31 December 2016: 728,645,559 ordinary shares of Baht 1 each)		728,688	728,645	728,688	728,645
1,363,365 preference shares of Baht 1 each (31 December 2016: 1,406,663 preference shares of Baht 1 each)		1,364	1,407	1,364	1,407
		<u>730,052</u>	<u>730,052</u>	<u>730,052</u>	<u>730,052</u>
Premium on ordinary shares		285,568	285,568	285,568	285,568
Convertible bonds treated as equity securities	2	550,000	550,000	550,000	550,000
Retained earnings					
Appropriated - statutory reserve		92,275	92,275	92,275	92,275
Unappropriated		13,475,658	12,657,987	13,391,109	12,605,831
Other components of shareholders' equity		156,609	157,972	-	-
Equity attributable to owners of the Company		<u>15,290,162</u>	<u>14,473,854</u>	<u>15,049,004</u>	<u>14,263,726</u>
Non-controlling interests of the subsidiaries		311,275	314,093	-	-
Total shareholders' equity		<u>15,601,437</u>	<u>14,787,947</u>	<u>15,049,004</u>	<u>14,263,726</u>
Total liabilities and shareholders' equity		<u>22,160,286</u>	<u>21,329,863</u>	<u>21,506,864</u>	<u>20,718,264</u>
		-	-	-	-

The accompanying notes are an integral part of the financial statements.

.....
Directors
.....

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries**Income statement****For the three-month period ended 30 June 2017**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		
	Note	2017	2016	2017	2016
Revenues					
Revenues from hospital operations		4,416,004	4,336,885	4,262,033	4,211,749
Rental income		16,004	15,764	19,793	18,143
Interest income		27,483	29,533	25,577	28,330
Dividend income	4	-	-	50,000	55,000
Gain on exchange		-	9,900	839	6,478
Other income		12,103	14,997	16,242	15,376
Total revenues		4,471,594	4,407,079	4,374,484	4,335,076
Expenses					
Cost of hospital operations		2,519,207	2,550,002	2,437,251	2,475,456
Administrative expenses		735,543	757,633	724,094	745,693
Loss on exchange		1,464	-	-	-
Total expenses		3,256,214	3,307,635	3,161,345	3,221,149
Profit before share of profit from investments in associates, finance cost and income tax expenses					
		1,215,380	1,099,444	1,213,139	1,113,927
Share of profit from investments in associates	5	1,441	706	-	-
Profit before finance cost and income tax expenses		1,216,821	1,100,150	1,213,139	1,113,927
Finance cost		(38,807)	(55,017)	(38,741)	(55,017)
Profit before income tax expenses		1,178,014	1,045,133	1,174,398	1,058,910
Income tax expenses	12	(217,191)	(186,678)	(206,299)	(181,790)
Profit for the period		960,823	858,455	968,099	877,120
Profit attributable to:					
Equity holders of the Company		960,014	857,996	968,099	877,120
Non-controlling interests of the subsidiaries		809	459		
		960,823	858,455		
(Unit: Baht)					
Earnings per share					
13					
Basic earnings per share					
Profit attributable to equity holders of the Company		1.32	1.18	1.33	1.20
Diluted earnings per share					
Profit attributable to equity holders of the Company		1.11	0.99	1.12	1.01

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of comprehensive income

For the three-month period ended 30 June 2017

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2017	2016	2017	2016
Profit for the period	<u>960,823</u>	<u>858,455</u>	<u>968,099</u>	<u>877,120</u>
Other comprehensive income:				
<i>Other comprehensive income to be reclassified to income statement in subsequent periods:</i>				
Exchange differences on translation of financial statements in foreign currencies	<u>18,875</u>	<u>30,298</u>	<u>-</u>	<u>-</u>
Other comprehensive income for the period	<u>18,875</u>	<u>30,298</u>	<u>-</u>	<u>-</u>
Total comprehensive income for the period	<u><u>979,698</u></u>	<u><u>888,753</u></u>	<u><u>968,099</u></u>	<u><u>877,120</u></u>
Total comprehensive income attributable to:				
Equity holders of the Company	<u>975,137</u>	<u>882,399</u>	<u><u>968,099</u></u>	<u><u>877,120</u></u>
Non-controlling interests of the subsidiaries	<u>4,561</u>	<u>6,354</u>		
	<u><u>979,698</u></u>	<u><u>888,753</u></u>		

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries**Income statement****For the six-month period ended 30 June 2017**

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		2017	2016	2017	2016
Revenues					
Revenues from hospital operations		8,851,987	8,955,313	8,568,039	8,711,380
Rental income		32,421	31,412	38,715	36,173
Interest income		48,319	58,818	45,323	57,069
Dividend income	4	-	-	50,000	55,000
Gain on exchange		-	15,470	5,249	12,488
Other income		32,821	39,831	39,601	40,122
Total revenues		8,965,548	9,100,844	8,746,927	8,912,232
Expenses					
Cost of hospital operations		5,014,389	5,217,270	4,858,458	5,071,114
Administrative expenses		1,474,826	1,530,689	1,458,517	1,493,803
Loss on exchange		195	-	-	-
Total expenses		6,489,410	6,747,959	6,316,975	6,564,917
Profit before share of profit from investments in associates, finance cost and income tax expenses					
		2,476,138	2,352,885	2,429,952	2,347,315
Share of profit from investments in associates	5	2,307	729	-	-
Profit before finance cost and income tax expenses		2,478,445	2,353,614	2,429,952	2,347,315
Finance cost		(78,427)	(101,288)	(78,295)	(101,288)
Profit before income tax expenses		2,400,018	2,252,326	2,351,657	2,246,027
Income tax expenses	12	(437,093)	(421,324)	(418,748)	(412,421)
Profit for the period		1,962,925	1,831,002	1,932,909	1,833,606
Profit attributable to:					
Equity holders of the Company		1,965,302	1,835,749	1,932,909	1,833,606
Non-controlling interests of the subsidiaries		(2,377)	(4,747)		
		<u>1,962,925</u>	<u>1,831,002</u>		
(Unit: Baht)					
Earnings per share					
13					
Basic earnings per share					
Profit attributable to equity holders of the Company		2.70	2.52	2.65	2.52
Diluted earnings per share					
Profit attributable to equity holders of the Company		2.27	2.12	2.23	2.11

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of comprehensive income

For the six-month period ended 30 June 2017

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2017	2016	2017	2016
Profit for the period	<u>1,962,925</u>	<u>1,831,002</u>	<u>1,932,909</u>	<u>1,833,606</u>
Other comprehensive income:				
<i>Other comprehensive income to be reclassified to income statement in subsequent periods:</i>				
Exchange differences on translation of financial statements in foreign currencies	<u>(1,804)</u>	<u>(4,062)</u>	<u>-</u>	<u>-</u>
Other comprehensive income for the period	<u>(1,804)</u>	<u>(4,062)</u>	<u>-</u>	<u>-</u>
Total comprehensive income for the period	<u><u>1,961,121</u></u>	<u><u>1,826,940</u></u>	<u><u>1,932,909</u></u>	<u><u>1,833,606</u></u>
Total comprehensive income attributable to:				
Equity holders of the Company	<u>1,963,939</u>	<u>1,833,107</u>	<u><u>1,932,909</u></u>	<u><u>1,833,606</u></u>
Non-controlling interests of the subsidiaries	<u>(2,818)</u>	<u>(6,167)</u>		
	<u><u>1,961,121</u></u>	<u><u>1,826,940</u></u>		

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries**Statement of cash flows****For the six-month period ended 30 June 2017**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2017	2016	2017	2016
Cash flows from operating activities				
Profit before tax	2,400,018	2,252,326	2,351,657	2,246,027
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation	591,945	560,840	564,410	536,660
Bad debts and allowance for doubtful accounts	18,942	46,315	18,870	46,221
Reduction of cost of inventories to net realisable value	209	293	-	-
(Gain) loss on sales and write-off of equipment and computer software	(1,044)	265	(620)	249
Long-term employee benefits expenses	44,773	44,927	43,462	43,732
Share of profit from investments in associates	(2,307)	(729)	-	-
Interest income	(48,319)	(58,818)	(45,323)	(57,069)
Dividend income	-	-	(50,000)	(55,000)
Amortisation of debenture issuing costs to interest expenses	1,813	3,187	1,813	3,187
Interest expenses	76,614	98,101	76,482	98,101
Profit from operating activities before changes in operating assets and liabilities	3,082,644	2,946,707	2,960,751	2,862,108
Operating assets (increase) decrease				
Trade and other receivables	227,105	(35,133)	226,009	(27,764)
Inventories	3,760	8,135	9,502	9,842
Prepaid expenses	(8,943)	(26,583)	(12,901)	(26,004)
Other current assets	(14,147)	7,906	(8,733)	10,434
Other non-current assets	(10,608)	166	(10,619)	165
Operating liabilities increase (decrease)				
Trade and other payables	5,422	(32,987)	(6,782)	(49,668)
Accrued physicians' fees	(33,221)	(34,650)	(33,924)	(34,155)
Accrued expenses	(47,550)	(122,457)	(43,157)	(118,603)
Other current liabilities	118	9,989	1,083	4,870
Provision for long-term employee benefits	(11,217)	(2,759)	(9,996)	(2,759)
Cash flows from operating activities	3,193,363	2,718,334	3,071,233	2,628,466
Cash paid for corporate income tax	(384,105)	(387,657)	(372,425)	(377,866)
Net cash flows from operating activities	2,809,258	2,330,677	2,698,808	2,250,600

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries**Statement of cash flows (continued)****For the six-month period ended 30 June 2017**

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2017	2016	2017	2016
Cash flows from investing activities				
(Increase) decrease in short-term investments	(1,854,000)	317,600	(1,800,000)	393,000
Decrease in long-term loan to a related party	-	-	-	9,000
Acquisition of investment in a subsidiary	-	-	-	(115,000)
Acquisition of investment in an associate	(1,670)	-	-	-
Dividend received	-	-	50,000	55,000
Acquisition of land and equipment and payment of construction and medical equipment payables	(432,218)	(859,652)	(419,850)	(801,263)
Acquisition of computer software	(61,483)	(21,417)	(60,863)	(20,914)
Proceeds from sales of equipment	2,440	324	2,550	324
Interest income	48,319	58,818	45,323	57,086
Net cash flows used in investing activities	(2,298,612)	(504,327)	(2,182,840)	(422,767)
Cash flows from financing activities				
Increase in long-term loan from an unrelated party	-	19,073	-	-
Interest paid for long-term debentures	(84,842)	(116,368)	(84,842)	(116,368)
Interest paid for convertible bonds treated as equity securities	(16,384)	(16,384)	(16,384)	(16,384)
Dividend paid	(1,129,351)	(1,057,050)	(1,129,351)	(1,057,050)
Net cash flows used in financing activities	(1,230,577)	(1,170,729)	(1,230,577)	(1,189,802)
Increase in translation adjustment	4,966	2,747	-	-
Net increase (decrease) in cash and cash equivalents	(714,965)	658,368	(714,609)	638,031
Cash and cash equivalents at beginning of period	5,154,161	5,054,160	4,938,523	4,818,341
Cash and cash equivalents at end of period	4,439,196	5,712,528	4,223,914	5,456,372
	-		-	
Supplemental cash flow information				
Non-cash transactions				
Interest capitalised as cost of assets	9,096	18,838	9,096	18,838
Increase (decrease) in construction and medical equipment payables	(18,427)	33,126	(18,427)	(5,038)

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity

For the six-month period ended 30 June 2017

(Unit: Thousand Baht)

Consolidated financial statements												
Equity attributable to owners of the Company												
				Other components of shareholders' equity								
				Other comprehensive income		Exchange differences						
Issued and paid-up share capital		Convertible bonds treated as equity securities		Retained earnings		on translation of financial statements in foreign currencies		Total other components of shareholders' equity		Total equity attributable to owners of the Company		
Ordinary shares	Preference shares	Premium on ordinary shares	Convertible bonds treated as equity securities	Appropriated	Unappropriated	statements in foreign currencies	Other surplus of an associated company	components of shareholders' equity	attributable to the Company	Equity attributable to non-controlling interests of the subsidiaries	Total shareholders' equity	
Balance as at 1 January 2016	728,625	1,427	285,568	550,000	92,275	10,799,084	26,534	252,173	278,707	12,735,686	364,804	13,100,490
Profit for the period	-	-	-	-	-	1,835,749	-	-	-	1,835,749	(4,747)	1,831,002
Other comprehensive income for the period	-	-	-	-	-	-	(2,642)	-	(2,642)	(2,642)	(1,420)	(4,062)
Total comprehensive income for the period	-	-	-	-	-	1,835,749	(2,642)	-	(2,642)	1,833,107	(6,167)	1,826,940
Preference shares converted to ordinary shares (Note 11)	20	(20)	-	-	-	-	-	-	-	-	-	-
Dividend paid (Note 15)	-	-	-	-	-	(1,058,340)	-	-	-	(1,058,340)	-	(1,058,340)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(16,117)	-	-	-	(16,117)	-	(16,117)
Balance as at 30 June 2016	728,645	1,407	285,568	550,000	92,275	11,560,376	23,892	252,173	276,065	13,494,336	358,637	13,852,973
Balance as at 1 January 2017	728,645	1,407	285,568	550,000	92,275	12,657,987	(94,201)	252,173	157,972	14,473,854	314,093	14,787,947
Profit for the period	-	-	-	-	-	1,965,302	-	-	-	1,965,302	(2,377)	1,962,925
Other comprehensive income for the period	-	-	-	-	-	-	(1,363)	-	(1,363)	(1,363)	(441)	(1,804)
Total comprehensive income for the period	-	-	-	-	-	1,965,302	(1,363)	-	(1,363)	1,963,939	(2,818)	1,961,121
Preference shares converted to ordinary shares (Note 11)	43	(43)	-	-	-	-	-	-	-	-	-	-
Dividend paid (Note 15)	-	-	-	-	-	(1,131,514)	-	-	-	(1,131,514)	-	(1,131,514)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(16,117)	-	-	-	(16,117)	-	(16,117)
Balance as at 30 June 2017	728,688	1,364	285,568	550,000	92,275	13,475,658	(95,564)	252,173	156,609	15,290,162	311,275	15,601,437
-	-	-	-	-	-	-	-	-	-	-	-	-

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity (continued)

For the six-month period ended 30 June 2017

(Unit: Thousand Baht)

Separate financial statements

	Issued and paid-up share capital		Premium on ordinary shares	Convertible bonds treated as equity securities	Retained earnings		Total shareholders' equity
	Ordinary shares	Preference shares			Appropriated	Unappropriated	
Balance as at 1 January 2016	728,625	1,427	285,568	550,000	92,275	10,703,897	12,361,792
Profit for the period	-	-	-	-	-	1,833,606	1,833,606
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	1,833,606	1,833,606
Preference shares converted to ordinary shares (Note 11)	20	(20)	-	-	-	-	-
Dividend paid (Note 15)	-	-	-	-	-	(1,058,340)	(1,058,340)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(16,117)	(16,117)
Balance as at 30 June 2016	<u>728,645</u>	<u>1,407</u>	<u>285,568</u>	<u>550,000</u>	<u>92,275</u>	<u>11,463,046</u>	<u>13,120,941</u>
Balance as at 1 January 2017	728,645	1,407	285,568	550,000	92,275	12,605,831	14,263,726
Profit for the period	-	-	-	-	-	1,932,909	1,932,909
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	1,932,909	1,932,909
Preference shares converted to ordinary shares (Note 11)	43	(43)	-	-	-	-	-
Dividend paid (Note 15)	-	-	-	-	-	(1,131,514)	(1,131,514)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(16,117)	(16,117)
Balance as at 30 June 2017	<u>728,688</u>	<u>1,364</u>	<u>285,568</u>	<u>550,000</u>	<u>92,275</u>	<u>13,391,109</u>	<u>15,049,004</u>
	-	-	-	-	-	-	-

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries

Notes to interim consolidated financial statements

For the three-month and six-month periods ended 30 June 2017

1. General information

1.1 Basis of preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 (revised 2016) Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, income, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language interim financial statements.

1.2 Basis of consolidation

These interim consolidated financial statements include the financial statements of Bumrungrad Hospital Public Company Limited and its subsidiaries (collectively "the Group") and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2016. There have been no changes in the composition of the Group during the current period.

1.3 New financial reporting standards

During the period, the Group has adopted the revised financial reporting standards and interpretations (revised 2016) and new accounting treatment guidance which is effective for fiscal years beginning on or after 1 January 2017. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards revision of wording and terminology, and provision of interpretations and accounting guidance to users of standards. The adoption of these financial reporting standards does not have any significant impact on the Group's financial statements.

1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2016.

2. Related party transactions

During the periods, the Company and its subsidiaries had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and those related parties.

(Unit: Million Baht)

	Consolidated		Separate		Pricing policy
	financial statements		financial statements		
	For the three-month periods ended 30 June		For the three-month periods ended 30 June		
	2017	2016	2017	2016	
Transactions with subsidiaries					
(eliminated from the consolidated financial statements)					
Medical service income	-	-	12.3	7.9	Market price
Professional service income	-	-	4.8	1.7	Actual paid and cost plus margin
Rental income	-	-	3.2	2.4	As per contracts
Sales of medicine and medical supplies	-	-	1.6	2.1	Cost plus margin
Dividend income	-	-	50.0	55.0	As declared
Lab service expenses	-	-	0.1	-	Market price
Pharmacy expenses	-	-	8.2	1.9	Market price
Training expenses	-	-	28.5	46.3	Cost plus margin
Service expenses	-	-	2.4	2.1	Cost plus margin
Rental expenses	-	-	0.4	-	As per contract
Transactions with an associate					
Interest expenses on long-term loan	0.6	0.6	0.6	0.6	1.38% p.a.
Transactions with related parties					
Medical service income	17.2	32.3	17.2	32.3	Market price
Rental income	0.7	0.7	0.7	0.7	Market price
Interest income on short-term investments	15.2	6.9	15.1	6.7	1.45% to 1.70% p.a. (2016: 1.58% to 1.80% p.a.)
Other income	0.1	0.2	0.1	0.2	At cost
Lab service expenses	4.8	3.2	4.8	3.2	Market price
Purchase of medicine and medical supplies	2.4	2.9	2.4	2.9	Market price
Donation expenses	8.0	8.4	8.0	8.4	-
Insurance expenses	7.1	7.5	7.0	7.5	As per insurance policies
Credit card commission fees	32.4	30.7	30.9	29.5	Market price
Legal advisory fees	0.9	1.0	0.7	0.9	Market price
Service expenses	0.8	0.1	0.8	0.1	Market price
Interest expenses on long-term debentures	10.5	11.6	10.5	11.6	4.59% and 4.97% p.a. (2016: 4.13% to 4.97% p.a.)
Interest expense on convertible bonds	8.1	8.1	8.1	8.1	10.00% and 1.00% p.a.

(Unaudited but reviewed)

(Unit: Million Baht)

	Consolidated		Separate		Pricing policy
	financial statements		financial statements		
	For the six-month		For the six-month		
	periods ended 30 June		periods ended 30 June		
	2017	2016	2017	2016	
Transactions with subsidiaries					
(eliminated from the consolidated financial statements)					
Medical service income	-	-	21.9	15.6	Market price
Professional service income	-	-	9.4	3.2	Actual paid and cost plus margin
Rental income	-	-	5.9	4.8	As per contracts
Sales of medicine and medical supplies	-	-	3.6	4.1	Cost plus margin
Sales of equipment	-	-	0.1	-	Market price
Dividend income	-	-	50.0	55.0	As declared
Lab service expenses	-	-	0.7	0.1	Market price
Pharmacy expenses	-	-	14.1	4.2	Market price
Training expenses	-	-	67.5	79.6	Cost plus margin
Service expenses	-	-	5.2	3.6	Cost plus margin
Rental expenses	-	-	0.4	-	As per contract
Transactions with an associate					
Consulting income	0.1	-	0.1	-	As per contracts
Interest expenses on long-term loan	1.2	1.2	1.2	1.2	1.38% p.a.
Transactions with related parties					
Medical service income	33.8	63.4	33.8	63.4	Market price
Rental income	1.4	1.3	1.4	1.3	Market price
Interest income on short-term investments	19.0	7.0	18.9	6.8	1.45% to 1.70% p.a. (2016: 1.58% to 1.80% p.a.)
Other income	0.4	0.4	0.4	0.4	At cost
Lab service expenses	6.2	5.8	6.2	5.8	Market price
Purchase of medicine and medical supplies	5.2	6.4	5.2	6.4	Market price
Donation expenses	16.0	15.2	16.0	15.2	-
Insurance expenses	14.2	15.5	14.1	15.4	As per insurance policies
Credit card commission fees	66.0	63.5	63.0	61.1	Market price
Legal advisory fees	1.4	1.3	1.2	1.2	Market price
Service expenses	0.8	0.3	0.8	0.3	Market price
Interest expenses on long-term debentures	20.9	23.1	20.9	23.1	4.59% and 4.97% p.a. (2016: 4.13% to 4.97% p.a.)
Interest expenses on convertible bonds	16.1	16.1	16.1	16.1	10.00% and 1.00% p.a.

(Unaudited but reviewed)

The balances of the accounts between the Company and those related parties are as follows.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	30 June 2017	31 December 2016	30 June 2017	31 December 2016
Short-term investments - fixed deposits with a local commercial bank				
Related company (common executive)	<u>3,354,000</u>	<u>1,509,000</u>	<u>3,309,000</u>	<u>1,509,000</u>
Trade and other receivables - related parties (Note 3)				
Subsidiaries	-	-	19,871	15,942
Associates	12	12	12	12
Related parties (common director)	<u>2,560</u>	<u>6,526</u>	<u>2,560</u>	<u>6,526</u>
Total	<u>2,572</u>	<u>6,538</u>	<u>22,443</u>	<u>22,480</u>
Trade and other payables - related parties (Note 8)				
Subsidiaries	<u>-</u>	<u>-</u>	<u>15,587</u>	<u>19,986</u>
Long-term loan from and interest payable to a related party				
Associate	<u>186,497</u>	<u>185,294</u>	<u>186,497</u>	<u>185,294</u>
Long-term debentures (Note 9)				
Related companies (major shareholders)	<u>855,000</u>	<u>855,000</u>	<u>855,000</u>	<u>855,000</u>
Convertible bonds treated as equity securities				
Related company (common executive)	<u>550,000</u>	<u>550,000</u>	<u>550,000</u>	<u>550,000</u>

Long-term loan from and interest payable to a related party

During the six-month period ended 30 June 2017, movements of long-term loan from and interest payable to an associate were as follows.

(Unit: Thousand Baht)

	Consolidated/ Separate financial statements			
	Balance as at	During the period		Balance as at
	1 January 2017	Increase	Decrease	30 June 2017
Bumrungrad International Ltd.				
Principal	176,400	-	-	176,400
Interest payable	<u>8,894</u>	<u>1,203</u>	-	<u>10,097</u>
Total	<u>185,294</u>	<u>1,203</u>	-	<u>186,497</u>

Directors and management's benefits

During the three-month and six-month periods ended 30 June 2017 and 2016, the Group had employee benefit expenses payable to their directors and management as follows.

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the three-month periods ended 30 June		For the three-month periods ended 30 June	
	2017	2016	2017	2016
Short-term employee benefits	20,448	35,672	17,812	32,899
Post employment benefits	1,159	2,228	1,070	2,025
Other long-term benefits	2	1	1	-
Total	21,609	37,901	18,883	34,924

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the six-month periods ended 30 June		For the six-month periods ended 30 June	
	2017	2016	2017	2016
Short-term employee benefits	42,867	63,647	37,826	57,632
Post employment benefits	2,317	4,309	2,140	4,049
Other long-term benefits	4	2	2	1
Total	45,188	67,958	39,968	61,682

3. Trade and other receivables

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	30 June	31 December	30 June	31 December
	2017	2016	2017	2016
<u>Trade receivables - related parties</u>				
Aged on the basis of due dates				
Not yet due	2,324	6,219	3,156	7,244
Total trade receivables - related parties	2,324	6,219	3,156	7,244
<u>Trade receivables - unrelated parties</u>				
Aged on the basis of due dates				
Not yet due	835,644	885,636	820,544	879,216
Past due				
1 - 30 days	208,872	6,007	206,648	3,882
31 - 60 days	1,336	159,420	257	157,076
61 - 90 days	93,045	109,129	91,275	101,314
91 - 180 days	218,914	233,074	217,395	232,919
181 - 365 days	91,012	283,765	91,009	283,765
More than 365 days	238,298	239,030	238,298	239,030
Total	1,687,121	1,916,061	1,665,426	1,897,202
Less: Allowance for doubtful accounts	(245,756)	(234,269)	(245,755)	(234,269)
Total trade receivables - unrelated parties, net	1,441,365	1,681,792	1,419,671	1,662,933
Total trade receivables - net	1,443,689	1,688,011	1,422,827	1,670,177
<u>Other receivables</u>				
Other receivables - related parties	248	319	19,287	15,236
Other receivables - unrelated parties	5,489	7,143	5,252	6,832
Total other receivables	5,737	7,462	24,539	22,068
Total trade and other receivables - net	1,449,426	1,695,473	1,447,366	1,692,245

(Unaudited but reviewed)

4. Investments in subsidiaries

Details of investments in subsidiaries as presented in the separate financial statements are as follows.

(Unit: Thousand Baht)

Company	Paid-up capital		Shareholding percentage		Cost		Allowance for loss on impairment		Carrying amounts based on cost method - net	
	30 June	31 December	30 June	31 December	30 June	31 December	30 June	31 December	30 June	31 December
	2017	2016	2017	2016	2017	2016	2017	2016	2017	2016
			(%)	(%)						
Vitalife Corporation Ltd.	Baht 31.5 million	Baht 31.5 million	100	100	25,610	25,610	-	-	25,610	25,610
Asia Global Research Co., Ltd.	Baht 50 million	Baht 50 million	100	100	50,000	50,000	(50,000)	(50,000)	-	-
Ruenmongkol Co., Ltd.	Baht 340 million	Baht 340 million	100	100	1,045,034	1,045,034	-	-	1,045,034	1,045,034
Bumrungrad Health Network Co., Ltd.	Baht 120 million	Baht 120 million	100	100	120,000	120,000	-	-	120,000	120,000
Bumrungrad Personnel Development and Training Center Co., Ltd.	Baht 5 million	Baht 5 million	100	100	5,000	5,000	-	-	5,000	5,000
Asia Global Health Ltd.	HKD 7.1 million	HKD 7.1 million	100	100	31,558	31,558	(29,500)	(29,500)	2,058	2,058
Life and Longevity Ltd.	USD 82,000	USD 82,000	100	100	2,860	2,860	-	-	2,860	2,860
Health Horizons Enterprises Pte. Ltd.	USD 16.8 million	USD 16.8 million	80	80	436,211	436,211	-	-	436,211	436,211
Bumrungrad Services Co., Ltd.	Baht 2 million	Baht 2 million	100	100	2,000	2,000	-	-	2,000	2,000
Total					<u>1,718,273</u>	<u>1,718,273</u>	<u>(79,500)</u>	<u>(79,500)</u>	<u>1,638,773</u>	<u>1,638,773</u>

(Unaudited but reviewed)

During the periods, the Company received dividends from a subsidiary in the separate financial statements as follow.

(Unit: Thousand Baht)

Company's name	Separate financial statements			
	For the three-month periods ended 30 June		For the six-month periods ended 30 June	
	2017	2016	2017	2016
Bumrungrad Personnel Development and Training Center Co., Ltd.	50,000	55,000	50,000	55,000
Total	50,000	55,000	50,000	55,000

Capital increase of a subsidiary

On 24 April 2017, the shareholders' meeting of Bumrungrad Mongolia LLC., a subsidiary held by Health Horizons Enterprises Pte. Ltd. (the Company's subsidiary), passed a resolution to increase the registered share capital from MNT 4,141 million (4.14 million ordinary shares with a par value of MNT 1,000 each) to MNT 4,181 million (4.18 million ordinary shares with a par value of MNT 1,000 each), by issuing additional MNT 0.04 million ordinary shares with a par value of MNT 1,000 each, or equivalent to approximately Baht 1 million, to the existing shareholder. Health Horizons Enterprises Pte. Ltd. acquired all of the additional shares. The subsidiary registered the increase of its share capital on 3 May 2017.

5. Investments in associates

5.1 Details of investments in associates

(Unit: Thousand Baht)

Company	Nature of business	Country of incorporation	Consolidated financial statements					
			Shareholding percentage		Cost		Carrying amounts based on equity method	
			30 June 2017	31 December 2016	30 June 2017	31 December 2016	30 June 2017	31 December 2016
<u>An associate held by the Company</u>			(%)	(%)				
Bumrungrad International Ltd.	Holding company	Thailand	31.5	31.5	1,447	1,447	238,711	236,280
<u>An associate held by the subsidiary</u>								
Inovital International AG (held by LLL)	Manufacture and sale of vitamin supplement products	Swiss Confederation	49.0	-	1,670	-	1,519	-
Total					3,117	1,447	240,230	236,280

(Unit: Thousand Baht)

Company	Separate financial statements			
	Shareholding percentage		Carrying amounts based on cost method	
	30 June 2017	31 December 2016	30 June 2017	31 December 2016
	(%)	(%)		
Bumrungrad International Ltd.	31.5	31.5	1,447	1,447
Total			1,447	1,447

5.2 Share of profit (loss) and dividend received

During the periods, the Company recognised its share of profit (loss) from investments in the associates as follows.

(Unit: Thousand Baht)

Company	Consolidated financial statements			
	For the three-month periods ended 30 June		For the six-month periods ended 30 June	
	2017	2016	2017	2016
Bumrungrad International Ltd.	1,565	706	2,431	729
Inovital International AG (held by LLL)	(124)	-	(124)	-
Total	1,441	706	2,307	729

During the three-month and six-month periods ended 30 June 2017 and 2016, the Company had no dividend received from the associates.

Acquisition of a new associate

On 20 January 2017, Life and Longevity Ltd. (LLL), the Company's wholly-owned subsidiary which is registered in Hong Kong Special Administrative Region of the People's Republic of China, acquired 49% of the common shares of Inovital International AG which is incorporated in Swiss Confederation, for CHF 49,000 (490 ordinary shares with a par value of CHF 100 each). That company is principally engaged in manufacture and sale of vitamin supplement products and after sales services.

6. Property, plant and equipment

(Unit: Thousand Baht)

	Consolidated financial statements	Separate financial statements
Net book value as at 1 January 2017	11,579,033	9,981,453
Acquisitions during period - at cost	413,791	401,423
Capitalisation of interest cost	9,096	9,096
Disposals and write-off during the period - net book value at disposal and write-off date	(1,393)	(1,927)
Depreciation for the period	(544,242)	(517,195)
Translation adjustments	(1,442)	-
Net book value as at 30 June 2017	11,454,843	9,872,850

(Unaudited but reviewed)

As at 30 June 2017, the Company had an outstanding balance of land, work under construction of building and building improvement of Baht 1,584 million (31 December 2016: Baht 1,414 million), which have been financed by long-term debentures and borrowing costs totaling Baht 9 million were capitalised during the six-month period ended 30 June 2017 (2016: Baht 14 million). The weighted average rate used to determine the amount of borrowing costs eligible for capitalisation was 4.97% p.a. (2016: 4.87% p.a.).

7. Goodwill

The change in the goodwill account is due to the impact of exchange differences on translation of the foreign operation's financial statements.

8. Trade and other payables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	30 June	31 December	30 June	31 December
	2017	2016	2017	2016
Trade payables - unrelated parties	734,865	735,780	706,590	715,629
Construction and medical equipment payables	83,442	101,869	83,442	101,869
Other payables - related parties	-	-	15,587	19,986
Other payables - unrelated parties	46,465	37,965	40,845	32,026
Total trade and other payables	<u>864,772</u>	<u>875,614</u>	<u>846,464</u>	<u>869,510</u>

9. Long-term debentures

As at 30 June 2017 and 31 December 2016, long-term debentures are as below.

(Unit: Thousand Baht)

	Consolidated/ Separate	
	financial statements	
	30 June 2017	31 December 2016
Long-term debentures	3,500,000	3,500,000
Less: Deferred debenture issuing costs	(13,646)	(15,459)
Long-term debentures - net	<u>3,486,354</u>	<u>3,484,541</u>

The long-term debentures are unsecured and unsubordinated debentures in Baht currency with fixed interest rates. Their fair value as at 30 June 2017 amounted to Baht 3,791 million (31 December 2016: Baht 3,781 million). The fair value hierarchy is level 2 and there are no transfers within the fair value hierarchy during the period.

Under the terms and conditions of the debentures, the Company has to comply with certain restrictions and maintain certain financial ratios which include:

- a) maintenance of a net debt to equity ratio not exceeding 1.75:1
- b) maintenance of a net debt to EBITDA ratio not exceeding 3.25:1

10. Provision for long-term employee benefits

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
As at 1 January 2017	492,516	485,802
Increase during the period	44,773	43,462
Utilised	(11,217)	(9,996)
As at 30 June 2017	<u>526,072</u>	<u>519,268</u>

11. Share capital

In the first quarter of 2017, 43,298 preference shares (2016: 20,000 shares) were converted into ordinary shares at ratio of one preference share to one ordinary share. The Company registered this conversion with the Ministry of Commerce on 7 March 2017.

12. Income tax

Interim corporate income tax was calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month and six-month periods ended 30 June 2017 and 2016 are made up as follows.

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the three-month periods ended 30 June		For the three-month periods ended 30 June	
	2017	2016	2017	2016
Current income tax:				
Interim corporate income tax charge	226,151	201,165	215,877	195,898
Deferred tax:				
Relating to origination and reversal of temporary differences	(8,960)	(14,487)	(9,578)	(14,108)
Income tax expenses reported in the income statements	<u>217,191</u>	<u>186,678</u>	<u>206,299</u>	<u>181,790</u>

(Unaudited but reviewed)

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the six-month periods ended 30 June		For the six-month periods ended 30 June	
	2017	2016	2017	2016
Current income tax:				
Interim corporate income tax charge	457,378	451,089	439,043	441,298
Deferred tax:				
Relating to origination and reversal of temporary differences	(20,285)	(29,765)	(20,295)	(28,877)
Income tax expenses reported in the income statements	<u>437,093</u>	<u>421,324</u>	<u>418,748</u>	<u>412,421</u>

13. Earnings per share

Basic earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period.

Diluted earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period plus the weighted average number of ordinary shares which would need to be issued to convert all dilutive potential ordinary shares into ordinary shares. The calculation assumes that the conversion took place either at the beginning of the period or on the date the potential ordinary shares were issued.

The following tables set forth the computation of basic and diluted earnings per share.

	Consolidated financial statements					
	For the three-month periods ended 30 June					
	Profit for the period		Weighted average number of ordinary shares		Earnings per share	
	2017	2016	2017	2016	2017	2016
(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)	
Basic earnings per share						
Profit attributable to equity holders of the Company	960,014	857,996	728,688	728,645	1.32	1.18
Effect of dilutive potential ordinary shares						
Preference shares	-	-	1,364	1,407		
Convertible bonds	-	-	137,363	137,363		
Diluted earnings per share						
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares	<u>960,014</u>	<u>857,996</u>	<u>867,415</u>	<u>867,415</u>	1.11	0.99

(Unaudited but reviewed)

Separate financial statements					
For the three-month periods ended 30 June					
Profit for the period		Weighted average number of ordinary shares		Earnings per share	
2017	2016	2017	2016	2017	2016
(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share					
Profit attributable to equity holders of the Company					
968,099	877,120	728,688	728,645	1.33	1.20
Effect of dilutive potential ordinary shares					
Preference shares					
-	-	1,364	1,407		
Convertible bonds					
-	-	137,363	137,363		
Diluted earnings per share					
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares					
<u>968,099</u>	<u>877,120</u>	<u>867,415</u>	<u>867,415</u>	1.12	1.01

Consolidated financial statements					
For the six-month periods ended 30 June					
Profit for the period		Weighted average number of ordinary shares		Earnings per share	
2017	2016	2017	2016	2017	2016
(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share					
Profit attributable to equity holders of the Company					
1,965,302	1,835,749	728,673	728,638	2.70	2.52
Effect of dilutive potential ordinary shares					
Preference shares					
-	-	1,379	1,414		
Convertible bonds					
-	-	137,363	137,363		
Diluted earnings per share					
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares					
<u>1,965,302</u>	<u>1,835,749</u>	<u>867,415</u>	<u>867,415</u>	2.27	2.12

Separate financial statements					
For the six-month periods ended 30 June					
Profit for the period		Weighted average number of ordinary shares		Earnings per share	
2017	2016	2017	2016	2017	2016
(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share					
Profit attributable to equity holders of the Company					
1,932,909	1,833,606	728,673	728,638	2.65	2.52
Effect of dilutive potential ordinary shares					
Preference shares					
-	-	1,379	1,414		
Convertible bonds					
-	-	137,363	137,363		
Diluted earnings per share					
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares					
<u>1,932,909</u>	<u>1,833,606</u>	<u>867,415</u>	<u>867,415</u>	2.23	2.11

14. Segment information

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance.

The Group has only one main reportable operating segment, which is the hospital and health care center business, and the major geographical area of its operations is Thailand, with its overseas operations not being material. Segment performance is measured based on operating profit or loss, on a basis consistent with that used to measure operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain exclusively to the aforementioned reportable operating segment.

15. Dividend paid

The Company declared dividend during the six-month periods ended 30 June 2017 and 2016 as follows.

Dividend	Approved by	Dividend paid (Thousand Baht)	Dividend per share (Baht)
Final dividend for 2016	Annual General Meeting of the shareholder on 26 April 2017	1,131,514	1.55
Final dividend for 2015	Annual General Meeting of the shareholder on 27 April 2016	1,058,340	1.45

16. Commitments and contingent liabilities**16.1 Capital commitments**

As at 30 June 2017 and 31 December 2016, the Group has capital commitments as below.

Details of Commitments	(Unit: Million Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	30 June 2017	31 December 2016	30 June 2017	31 December 2016
1) Design and renovation agreements of buildings	574	691	560	689
2) Purchase of medical instruments and hospital equipment	11	95	9	91
3) Purchase of computer software agreements	329	368	329	368

16.2 Operating lease and long-term service commitments

The Company has entered into operating lease agreements in respect of the lease of lands, buildings, office space, vehicles and equipment and long-term service agreements. The terms of the agreements are generally between 1 and 30 years.

As at 30 June 2017 and 31 December 2016, future minimum payments required under the above agreements were as follows.

(Unit: Million Baht)

Details of commitments	Consolidated financial statements					
	Payable within					
	1 year		1 to 5 years		More than 5 years	
	30 June 2017	31 December 2016	30 June 2017	31 December 2016	30 June 2017	31 December 2016
1) Nursing dormitory land rental expense (shall be extended for a further period of 30 years)	1	1	4	4	-	1
2) Lease of office space	10	24	1	1	-	-
3) Maintenance service fee for medical instruments	144	167	159	214	3	4
4) Rental and maintenance service fee for cars	13	13	20	25	-	-
5) Service fee for medical treatment information database	59	42	181	230	-	-
6) Maintenance service fee for computer system	30	7	31	61	-	-

(Unit: Million Baht)

Details of commitments	Separate financial statements					
	Payable within					
	1 year		1 to 5 years		More than 5 years	
	30 June 2017	31 December 2016	30 June 2017	31 December 2016	30 June 2017	31 December 2016
1) Nursing dormitory land rental expense (shall be extended for a further period of 30 years)	1	1	4	4	-	1
2) Lease of office space	13	24	4	-	-	-
3) Maintenance service fee for medical instruments	136	157	154	204	3	4
4) Rental and maintenance service fee for cars	12	12	19	22	-	-
5) Service fee for medical treatment information database	59	42	181	230	-	-
6) Maintenance service fee for computer system	29	6	30	59	-	-

In addition, the Company has lease commitment for building space with a company for a period of 4 years ending 27 September 2020. Under the terms of the agreement, the Company agrees a rental fee at a rate based on the revenues and other information. In this regard, the minimum payment for rental fee within 2017 amounted to Baht 10 million.

16.3 Commitments from other contract

The Company entered into the medical equipment utilisation contract with a local company. The contract covers period of 7 years (expire in 2021) and under the conditions of the contract, the Company is required to purchase medical supplies and services to use with the medical equipment at the prices specified in the contract in total throughout the period of the contract. As at 30 June 2017, the outstanding amount of medical supplies and services that the Company is required to purchase in accordance with the contract is Baht 118 million (31 December 2016: Baht 159 million).

16.4 Uncalled portion of an investment in a subsidiary

As at 30 June 2017, the Company has commitment in respect of the uncalled portion of investment in an overseas subsidiary (Asia Global Health Ltd.) of HKD 2.34 million (31 December 2016: HKD 2.34 million).

16.5 Guarantees

As at 30 June 2017, there were outstanding bank guarantees of Baht 30 million (31 December 2016: Baht 30 million) issued by a bank on behalf of the Company. All were required in the normal course of business e.g. payment of utility expenses and space rental.

17. Event after the reporting period

On 9 August 2017, the Company's Board of Directors Meeting approved the payment of an interim dividend of Baht 1 per share to the Company's preference and ordinary shareholders from the Company's operations from 1 January 2017 to 30 June 2017. This constitutes a total dividend of Baht 730 million which will be paid on 6 September 2017.

18. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 9 August 2017.